Month: May 2020

– Advisory committee meeting not required; PDUFA goal date unchangedRockville, MD, May 28, 2020 (GLOBE NEWSWIRE) —MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that during the recent mid-cycle communication with the U.S. Food and Drug Administration (FDA), the FDA notified the Company that it is no longer planning to hold an Oncologic Drugs Advisory Committee (ODAC) meeting to discuss the Biologics License Application (BLA) for margetuximab. The FDA also stated it continues to anticipate meeting the Prescription Drug User Fee Act (PDUFA) goal date for the application review, which is December 18, 2020.“Since submitting the BLA for margetuximab, we have worked...

BOSTON, May 28, 2020 (GLOBE NEWSWIRE) — Today, DraftKings Sportsbook has announced it will offer live-streamed sports games within its award-winning mobile app. In collaboration with Sportradar, the global provider of sports data and content, DraftKings Sportsbook will provide customers with a seamless entertainment experience in one convenient location.Pursuant to state regulations, DraftKings Sportsbook customers who are logged in to their active accounts and have a wallet balance above $0.00 will have the ability to live stream games directly within the mobile app. At launch, DraftKings Sportsbook geolocated customers will be able to live stream a number of sports, including the Korea Baseball Organization and Bundesliga Soccer (Division 1) across all jurisdictions except Iowa. With over 100 different leagues in total on the...

TORONTO, May 28, 2020 (GLOBE NEWSWIRE) — Deveron UAS Corp. (CSE: DVR) (“Deveron” or the “Company”), a leading agriculture digital services and insights provider in North America, is pleased to announce revenue growth of 181% year over year to $283,420 in Q1 2020.  For the fourth quarter in a row, Deveron achieved sales growth of over 100%.First Quarter 2020 Financial and Operational HighlightsThe Company’s financial performance improved over the previous year’s quarter, driven by the continued customer uptake of Deveron’s soil sampling service.  For the three-month financial results ended March 31, 2020 (and comparable period ended March 31, 2019):Revenue grew 181% year over year to $283,420 in Q1 2020, from $100,564 in Q1 2019. Gross profit grew 160% year over year to $180,212 in Q1 2020, from $69,833 in Q1 2019.“Our first quarter...

The online learning program combines lab simulations and mentoring experiences focused on biotechnology and neurological diseases, such as Parkinson’s disease, Alzheimer’s disease and multiple sclerosisFour hundred students from Massachusetts and North Carolina are enrolling in this no-fee program that also provides students with computers and other technology resourcesThe initiative builds upon Biogen’s Community Lab, which has enrolled more than 55,000 students to date, and the Lemelson-MIT Program in inspiring the next generation of creative and inventive problem-solversCAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) is bringing its well-recognized Community Lab science learning program together with the Lemelson-MIT Program (LMIT) at the Massachusetts Institute of Technology to launch the new online...

Results from the ongoing, open-label extension (OLE) study of the pivotal NEURO-TTR trial published in the European Journal of Neurology show that patients treated with TEGSEDI® (inotersen) experienced sustained improvements in measures of neuropathic progression at 39 months of therapy, and clinically relevant improvements in measures of quality of life compared to the natural history of the diseaseNo new safety signals were identifiedTEGSEDI is an at-home subcutaneous injectionBOSTON and CARLSBAD, Calif., May 28, 2020 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced publication of long-term data from the open-label extension (OLE) of the pivotal NEURO-TTR study of TEGSEDI® (inotersen) in patients...

CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 4th at 4:30 p.m. ET.A live audio webcast of the presentation will be available on the Investors section of the Evelo website at http://ir.evelobio.com/news-events. A replay of the webcast will be available for approximately 30 days following the presentation.About Evelo BiosciencesEvelo Biosciences is a clinical stage biotechnology company developing oral biologics that act on SINTAX™, the small intestinal axis, with systemic therapeutic effects. SINTAX plays a central role in governing the immune,...

MOUNTAIN VIEW, Calif., May 28, 2020 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Thursday, June 4 at 10:00 a.m. ET. The conference will be held in a virtual meeting format.A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.About IGM Biosciences, Inc. Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology...

 PRESS RELEASEErgomed to Present at Jefferies Virtual 2020 Healthcare ConferenceGuildford, UK – 28 May 2020: Ergomed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company focused on providing specialised services to the pharmaceutical industry, today announces that Richard Barfield, Chief Financial Officer of Ergomed, will present at the Jefferies Virtual Healthcare Conference at 2pm BST on 2 June 2020.A live webcast of the presentation will be available on Ergomed’s website, here:https://www.ergomedplc.com/investor-relations/reports-and-presentations/ENDSEnquiries:About Ergomed plcErgomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, profitable services business includes...

WALTHAM, Mass., May 28, 2020 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company has initiated a Phase 1/2 clinical study of APL-9, an investigational C3 inhibitor designed for acute interventions, in COVID-19 patients with respiratory failure including acute respiratory distress syndrome (ARDS). ARDS is a life-threatening form of lung failure that involves overactivation of complement, a part of the body’s immune system.1In COVID-19, complement activation has also been found to be strongly associated with organ failure and thrombotic events, which involve the abnormal formation of blood clots and are an emerging cause of mortality in COVID-19 patients.2,3,4 Apellis initiated the Phase 1/2 study following preliminary...

SHANGHAI, China, May 28, 2020 (GLOBE NEWSWIRE) — 360 Finance, Inc. (NASDAQ: QFIN) (“360 Finance” or the “Company”), a leading digital consumer finance platform, today announced that Mr. Dan Zhao has been appointed as a director on the board of directors of the Company (the “Board”), effective immediately.Mr. Dan Zhao is currently the vice president of 360 Group. Before joining 360 Group in January 2013, Mr. Zhao served as a senior manager of internal audit in Alibaba Group (NYSE: BABA) from November 2007. From September 2006 to November 2007, Mr. Zhao worked for KPMG Huazhen LLP as an associate manager. Mr. Zhao received his bachelor’s degree in international enterprise management from the University of Shanghai for Science and Technology in 2002, and his master’s degree in international business and economics from the University...